Recently, a second revision of the International Staging System 2 (R2-ISS) was developed using 16 randomized clinical trial datasets by the European Myeloma Network, although clinical trials on CD38-MoAb-containing initial treatments were not included [48]. The gene discussed is CD38; the disease is plasma cell myeloma.